GlaxoSmithKline seeks U.S. approval for triple lung drug

GlaxoSmithKline seeks U.S. approval for triple lung drug


GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light. Britain's biggest drugmaker is vying with competitors including AstraZeneca and Novartis to develop so-called "closed triple" therapies, offering a single inhaler for patients with chronic obstructive pulmonary disease .



from Biotech News